Ontology highlight
ABSTRACT:
SUBMITTER: Dotan E
PROVIDER: S-EPMC2844047 | biostudies-other | 2010 Mar
REPOSITORIES: biostudies-other
Dotan Efrat E Aggarwal Charu C Smith Mitchell R MR
P & T : a peer-reviewed journal for formulary management 20100301 3
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults, with B-cell lymphomas accounting for 85% of all NHLs. The most substantial advancement in the treatment of B-cell malignancies, since the advent of combination chemotherapy, has been the addition of the monoclonal anti-CD20 antibody rituximab (Rituxan). Since its initially reported single-agent activity in indolent lymphomas in 1997, the role of rituximab has expanded to cover both indolent and aggressive lymphom ...[more]